{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:43:38Z","timestamp":1761561818972},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mrs G is a 54-year-old woman with a diagnosis of chronic-phase chronic myeloid leukemia dating back 8 years. She had a low-risk Sokal score at diagnosis and was started on imatinib mesylate at 400 mg orally daily within one month of her diagnosis. Her 3-month evaluation revealed a molecular response measured by quantitative RT-PCR of 1.2% by the International Scale. Within 6 months of therapy, she achieved a complete cytogenetic response, and by 18 months, her BCR-ABL1 transcript levels were undetectable using a quantitative RT-PCR assay with a sensitivity of \u2265 4.5 logs. She has maintained this deep level of response for the past 6.5 years. Despite her excellent response to therapy, she continues to complain of fatigue, intermittent nausea, and weight gain. She is asking to discontinue imatinib mesylate and is not interested in second-line therapy. Is this a safe and reasonable option for this patient?<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.184","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"184-188","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?"],"prefix":"10.1182","volume":"2013","author":[{"given":"Kendra","family":"Sweet","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center, University of South Florida, Tampa, FL; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Oehler","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"11","key":"2019111702462259100_B1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111702462259100_B2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111702462259100_B3","first-page":"1676","article-title":"ENESTnd 4-year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) [abstract]","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"2019111702462259100_B4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"2019111702462259100_B5","first-page":"6504","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up","volume":"30","author":"Hochhaus","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"10","key":"2019111702462259100_B6","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111702462259100_B7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","article-title":"Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111702462259100_B8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","article-title":"Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison","volume":"21","author":"Phillips","year":"2013","journal-title":"Support Care Cancer"},{"issue":"22","key":"2019111702462259100_B9","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Leukemia EiCM","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2019111702462259100_B10","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1182\/blood-2012-09-458463","article-title":"Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy","volume":"120","author":"Aduwa","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111702462259100_B11","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111702462259100_B12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111702462259100_B13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111702462259100_B14","first-page":"2788","article-title":"Detailed investigation on characteristics of Japanese patients with chronic phase CML who achieved a durable CMR after discontinuation of imatinib\u2013an updated result of the Keio STIM study [abstract]","volume":"120","author":"Matsuki","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111702462259100_B15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response","volume":"36","author":"Yhim","year":"2012","journal-title":"Leuk Res"},{"issue":"1","key":"2019111702462259100_B16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111702462259100_B17","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3324\/haematol.2011.048165","article-title":"Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features","volume":"96","author":"Ross","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"2019111702462259100_B18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00257.x","article-title":"Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia","volume":"72","author":"Ghanima","year":"2004","journal-title":"Eur J Haematol"},{"key":"2019111702462259100_B19","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"issue":"7","key":"2019111702462259100_B20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/10428190802043903","article-title":"Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha","volume":"49","author":"Verma","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111702462259100_B21","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"issue":"7","key":"2019111702462259100_B22","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"21","key":"2019111702462259100_B23","first-page":"916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts [abstract]","volume":"120","author":"Rea","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702462259100_B24","first-page":"2763","article-title":"Discontinuation of imatinib therapy in chronic myeloid leukemia patients with sustained complete molecular response 4.5 (CMR4.5) [abstract]","volume":"118","author":"Goh","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702462259100_B25","first-page":"3783","article-title":"Patient (pt)-driven discontinuation of tyrosine kinase inhibitor therapy in chronic phase chronic myeloid leukemia (CML)\u2013single institution experience [abstract]","volume":"120","author":"Benjamini","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"2019111702462259100_B26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3109\/10428194.2011.649753","article-title":"Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors","volume":"53","author":"Aoki","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2019111702462259100_B27","first-page":"3765","article-title":"Discontinuation of imatinib in patients with CML and sustained complete molecular response (CMR) for over 2 years in the Japanese Population\u2013an interim analysis of the Keio STIM study [abstract]","volume":"118","author":"Matsuki","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702462259100_B28","first-page":"604","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: results from the French CML group (FILMC) [abstract]","volume":"118","author":"Rea","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702462259100_B29","first-page":"165","article-title":"Early molecular response and female sex strongly predict achievement of stable undetectable BCR-ABL1, a criterion for imatinib discontinuation in patients with CML [abstract]","volume":"120","author":"Branford","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111702462259100_B30","first-page":"4401","article-title":"Discontinuation of BCR-ABL1 tyrosine kinase inhibitor in CML patients with undetectable molecular residual disease for at least 1 year: including updated data from KIDS study","author":"Oh Y","year":"2013"},{"key":"2019111702462259100_B31","article-title":"Frequent and sustained drug-free remission in the Australian CML8 Trial of imatinib withdrawal","author":"Ross","year":"2012"},{"issue":"5","key":"2019111702462259100_B32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11912-012-0253-9","article-title":"Chronic myeloid leukemia: state of the art in 2012","volume":"14","author":"Fava","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"21","key":"2019111702462259100_B33","first-page":"3781","article-title":"Fluctuating values of molecular residual disease (MRD) without molecular progression after imatinib discontinuation in patients (pts) with chronic myeloid leukemia (CML) who have maintained complete molecular response: implications for re-treatment criteria and role of prior interferon therapy\u2013a pilot study of the French CML group (FILMC) [abstract]","volume":"118","author":"Rousselot","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111702462259100_B34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","article-title":"Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature","volume":"33","author":"Guastafierro","year":"2009","journal-title":"Leuk Res"},{"issue":"6","key":"2019111702462259100_B35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","article-title":"Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy","volume":"50","author":"Goh","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111702462259100_B36","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2019111702462259100_B37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/asheducation-2011.1.136","article-title":"Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?","volume":"2011","author":"Melo","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111702462259100_B38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/asheducation.V2012.1.122.3798214","article-title":"Is going for cure in chronic myeloid leukemia possible and justifiable?","volume":"2012","author":"Mahon","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2019111702462259100_B39","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"issue":"19","key":"2019111702462259100_B40","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111702462259100_B41","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111702462259100_B42","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111702462259100_B43","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111702462259100_B44","first-page":"7052","article-title":"Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update","volume":"31","author":"Larson","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"issue":"9","key":"2019111702462259100_B45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"24","key":"2019111702462259100_B46","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111702462259100_B47","first-page":"603","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: updated results of the STIM study [abstract]","volume":"118","author":"Mahon","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111702462259100_B48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/184\/1249615\/bep00113000184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/184\/1249615\/bep00113000184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:46:37Z","timestamp":1573976797000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/184\/20747\/Discontinuation-of-tyrosine-kinase-inhibitors-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.184","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}